Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Xinlu Liu

Internal Medicine Columbia, SC Medical Doctor

NPI 1831553502 CMS profile 5962113

1301 Taylor St Ste 8A, Columbia, SC 29201

Open in the dashboard

General payments

$3,850

163 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Xinlu Liu of Columbia, SC is reported in the CMS Open Payments database as having received $3,850 across 163 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $750 45
2024 General $703 40
2023 General $919 40
2022 General $691 28
2021 General $565 7
2020 General $148 2
2019 General $74 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Xinlu Liu
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Xinlu Liu were reported at $750. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Xinlu Liu Internal Medicine median Middle half National median
2019 $74 $159 $48–$570 $163
2020 $148 $119 $33–$402 $114
2021 $565 $135 $37–$521 $132
2022 $691 $141 $42–$496 $149
2023 $919 $149 $45–$519 $160
2024 $703 $154 $47–$537 $164
2025 $750 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $609 41 payments
  2. Novo Nordisk Inc $598 20 payments
  3. Pfizer Inc. $407 23 payments
  4. AstraZeneca Pharmaceuticals LP $385 13 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $277 8 payments
  6. Lilly USA, LLC $247 9 payments
  7. Biohaven Pharmaceuticals, Inc. $241 2 payments
  8. Abbott Laboratories $209 10 payments
  9. Novartis Pharmaceuticals Corporation $155 7 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $152 3 payments
  11. Other $571 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,839 162 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. NURTEC ODT Primary Care $393 5 payments
  2. UBRELVY $334 19 payments
  3. NURTEC ODT Pain $310 17 payments
  4. Kerendia $277 8 payments
  5. Ozempic $271 8 payments
  6. QULIPTA $261 20 payments
  7. ZAVZPRET $189 10 payments
  8. MOUNJARO $182 5 payments
  9. Wegovy $145 7 payments
  10. COMIRNATY $133 8 payments
  11. Other $2,311 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 144 drugs

Part D claims

6,584

Median for Internal Medicine: 777

Drug cost

$994,663

Median for Internal Medicine: $73,373

Branded share of claims

29.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 172 $305,479
Mounjaro Tirzepatide Brand 54 $101,026
Eliquis Apixaban Brand 58 $75,782
Jardiance Empagliflozin Brand 59 $68,181
Farxiga Dapagliflozin Propanediol Brand 54 $58,551
Trulicity Dulaglutide Brand 26 $42,357
Rybelsus Semaglutide Brand 22 $35,952
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 25 $30,289
Xarelto Rivaroxaban Brand 25 $26,315
Linzess Linaclotide Brand 26 $26,235

The 10 drugs with the highest cost, of 144 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$98,625

Of which drugs: $7,070

Medicare patients

259

Average age 71

Services billed

1,673

143 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 47%
Ischemic heart disease 32%
Diabetes 31%
Chronic kidney disease 21%
Atrial fibrillation 15%
Heart failure 14%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 39 41 $3,315

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $60
$60 — —
QULIPTA
  • AbbVie, Inc. $60
$60 — —
Wegovy
  • Novo Nordisk Inc $45
$45 — —
JARDIANCE
  • Lilly USA, LLC $26
  • Boehringer Ingelheim Pharmaceuticals, Inc. $15
$41 59 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

163 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record